[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362514-105":59,"doc-detail-362514-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-optimization-of-bexmarilimab-as-a-myeloid-checkpoint-therapy","Clinical optimization of bexmarilimab as a myeloid checkpoint therapy","","Checkpoint blockade has transformed cancer therapy, yet durable responses are constrained by myeloid-driven immunosuppression. Bexmarilimab, a first-in-class monoclonal antibody targeting Clever-1 (Stabilin-1), aims to recondition tumor-associated macrophages and malignant myeloid cells. This review consolidates the biological rationale for Clever-1 targeting, evaluates clinical and translational evidence, and proposes routes to improve efficacy via patient selection, rational combinations, biomarker-based stratification, and optimized intervention timing.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-optimization-of-bexmarilimab-as-a-myeloid-checkpoint-therapy/362514/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-optimization-of-bexmarilimab-as-a-myeloid-checkpoint-therapy/362514.png","ImageObject",300,407,{"name":92,"@type":93},"WPS_1786070896","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-24","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":19},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main problem addressed by myeloid checkpoint therapy?","Question",{"text":112,"@type":113},"Durable checkpoint blockade responses are limited because tumors remain refractory due to persistent immunosuppressive myeloid populations in the tumor microenvironment.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does bexmarilimab target myeloid checkpoint signaling?",{"text":117,"@type":113},"Bexmarilimab is a first-in-class antibody against Clever-1 (Stabilin-1), a receptor expressed on immunosuppressive macrophages, where blockade impairs lipid uptake and endosomal trafficking to enhance antigen processing and promote pro-inflammatory macrophage programming.",{"name":119,"@type":110,"acceptedAnswer":120},"Why is patient selection and biomarker stratification important for bexmarilimab?",{"text":121,"@type":113},"Because single-agent activity is modest in heavily pretreated metastatic patients, identifying patients most likely to benefit—either with monotherapy or rational combinations—helps avoid unnecessary escalation to complex multiagent regimens.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},362514,1790229918,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":19,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549768072016,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","REVIEW  \nClinical optimization of bexmarilimab as a myeloid checkpoint therapy  \nMahalakshmi Karthikeyana,b,c, Jesper Mickosa,b,c and Maija Hollména,b,d  \naMediCity Research Laboratory, University of Turku, Turku, Finland; bInFLAMES Flagship, University of Turku, Turku, Finland; cImmuDocs Doctoral Program, University of Turku, Turku, Finland; dR&D and Discovery, Faron Pharmaceuticals, Turku, Finland  \nABSTRACT  \nCheckpoint blockade has revolutionized cancer therapy, yet durable responses are limited by myeloiddriven immunosuppression. Bexmarilimab, a first-in-class monoclonal antibody targeting the scavenger receptor Clever-1 (Stabilin-1), represents a novel strategy to recondition tumor-associated macrophages and malignant myeloid cells. This review summarizes the biological rationale for Clever-1 targeting, appraises clinical and translational evidence, and outlines strategies to enhance therapeutic efficacy through patient selection, rational drug combinations, biomarker-driven patient stratification, and timing of intervention. We also highlight future opportunities for integrating bexmarilimab with nextgeneration immunotherapies and precision medicine approaches.  \nARTICLE HISTORY  \nReceived 8 October 2025 Accepted 12 January 2026  \nKEYWORDS  \nCancer; Clever-1; tumorassociated macrophages; myeloid checkpoint blockade; immunotherapy; AML; MDS  \n1. Introduction-expanding the checkpoint paradigm beyond T cells  \nImmune checkpoint inhibitors have transformed cancer treatment, yet durable benefit is limited to a subset of patients. While PD-1/PD-L1 or CTLA-4 blockade reinvigorates exhausted T cells, many tumors remain refractory due to persistent immunosuppressive myeloid populations [1]. Tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells constitute a dominant immunoregulatory force within the tumor microenvironment (TME), blunting antigen presentation, suppressing CD8+ T-cell cytotoxicity, and promoting regulatory T-cell differentiation [2,3]. Targeting this myeloid axis has emerged as a promising therapeutic strategy [4,5].  \nIn this context, the term myeloid checkpoint has been introduced to describe inhibitory receptors and regulatory pathways within macrophages, monocytes, and dendritic cells that restrain antitumor immunity. Similar to T-cell checkpoints, these pathways, including SIRPα/CD47 [6], LILRBs [7], TIM-3 [8], VISTA [9], TREM2 [10], and MARCO [11], maintain myeloid cells in a suppressive or tolerogenic state, limiting phagocytosis, antigen presentation, and support for effector T-cell responses. As a result, myeloid checkpoint blockade represents a complementary immunotherapeutic approach aimed at releasing the suppressive constraints imposed by the innate immune compartment.  \nWhile the clinical translation of macrophage-reprogramming therapies is still evolving, the field has reached an important point of maturity with both opportunities and challenges ahead. A key priority is the development of predictive biomarkers that can identify patients most likely to benefit, either from single-agent activity or from specific rational combinations, thereby avoiding unnecessary escalation to complex multiagent regimens. At the same time, systematic comparison of  \nmechanistically related agents at earlier stages of development will be essential to distinguish the most promising strategies and streamline progress. Although durable single-agent responses remain uncommon, these refinements in patientselection and trial design have the potential to unlock the full therapeutic impact of macrophage-targeted approaches and accelerate their integration into clinical practice [12].  \nBexmarilimab is a first-in-class humanized monoclonal antibody against Clever-1 (also known as Stabilin-1), a multifunctional scavenger receptor expressed on immunosuppressive macrophages and sinusoidal endothelial cells [13]. Within the TME, Clever-1–positive macrophages orchestrate an antiinflammatory state that facilitates i","cbCaidEAhQC1gvhY","https://ap.wps.com/l/cbCaidEAhQC1gvhY","pdf",3363528,"English","# Introduction-expanding the checkpoint paradigm beyond T cells\n# Bexmarilimab as a Clever-1 targeting myeloid checkpoint therapy","[{\"question\":\"What is the main problem addressed by myeloid checkpoint therapy?\",\"answer\":\"Durable checkpoint blockade responses are limited because tumors remain refractory due to persistent immunosuppressive myeloid populations in the tumor microenvironment.\"},{\"question\":\"How does bexmarilimab target myeloid checkpoint signaling?\",\"answer\":\"Bexmarilimab is a first-in-class antibody against Clever-1 (Stabilin-1), a receptor expressed on immunosuppressive macrophages, where blockade impairs lipid uptake and endosomal trafficking to enhance antigen processing and promote pro-inflammatory macrophage programming.\"},{\"question\":\"Why is patient selection and biomarker stratification important for bexmarilimab?\",\"answer\":\"Because single-agent activity is modest in heavily pretreated metastatic patients, identifying patients most likely to benefit—either with monotherapy or rational combinations—helps avoid unnecessary escalation to complex multiagent regimens.\"}]","Clinical optimization of bexmarilimab as a myeloid checkpoint therapy | PDF",1790148062,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f074f69bb56383df7a617b9f35018a50.webp",983,1280,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ceb639f13ac1abe486f9be2ae8cc101a.webp",982,1278,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fc59dd3bcabcf2b8de62bf0c3cc0d4f7.webp",981,1277,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2c737c777573ca9d218950ce391c7e01.webp",980,1276]